Promise Tracker
0 delivered, 0 close, 4 missed.
View Promises →HUL delivered a steady Q3 FY26 with 6% revenue growth and 4% underlying volume growth, the highest in 12 quarters.
✓ Verified against BSE filing
HUL delivered a steady Q3 FY26 with 6% revenue growth and 4% underlying volume growth, the highest in 12 quarters. Growth was broad-based across all segments, with home care gaining its highest-ever market share and beauty & well-being led by double-digit hair care growth. EBITDA margin at 23.3% remained within the guided range, while PAT before exceptional items grew 1% to INR 2,562 crore. Management cited improving macros (lower inflation, supportive RBI policy) and internal actions (quick commerce organization, portfolio transformation) as key drivers. Guidance: H2 FY26 better than H1, and FY27 better than FY26, with margins staying in the 22-23% range. Risk: volatile input costs and currency depreciation could pressure margins if pricing actions lag.
HUL ने वित्त वर्ष 2026 की तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई में 6% और बिक्री की मात्रा में 4% की बढ़ोतरी हुई, जो पिछले 12 तिमाहियों में सबसे ज्यादा है। घरेलू देखभाल उत्पादों ने सबसे ज्यादा बाजार हिस्सेदारी हासिल की, जबकि बालों की देखभाल में दो अंकों की वृद्धि हुई। कंपनी का मुनाफा 1% बढ़कर 2,562 करोड़ रुपये रहा। प्रबंधन ने कहा कि महंगाई कम होने और RBI की मदद से हालात बेहतर हो रहे हैं। उन्होंने यह भी कहा कि अगली तिमाही इससे बेहतर रहेगी और अगले वित्त वर्ष में और सुधार होगा। हालांकि, कच्चे माल की कीमतें बढ़ने और रुपये के कमजोर होने से मुनाफे पर दबाव पड़ सकता है।
0 delivered, 0 close, 4 missed.
View Promises →Input cost volatility and currency depreciation
View Risks →Full transcript text is available on this route.
Read Transcript →Highest UVG in 12 quarters, driven by broad-based volume recovery across all categories.
Quick commerce is doubling every quarter; HUL set up a dedicated organization to capture this channel.
Combined annualized revenue run-rate of Minimalist and OZiva, reflecting strong D2C scaling.
Availability improved by 1,400 basis points over the past year due to supply chain investments.
Management expects FY27 top-line growth to exceed FY26, driven by improving macros and internal actions.
Second half of FY26 is expected to show stronger growth than the first half, with Q3 as a normalized base.
Consolidated EBITDA margin will remain within the guided range of 22-23% (excluding ice cream), as growth investments are prioritized.
Calibrated price increases across portfolio, especially in home care, to offset input cost inflation.
Ice cream demerger expected to complete in December quarter, with listing in Q4 FY26, subject to regulatory approvals.
Depreciating rupee and divergent commodity trends (palm oil, tea, crude derivatives) could pressure margins if price increases lag.
Home care pricing has been negative for an extended period due to competitive intensity; recovery may be gradual.
Analyst noted HUL's skincare growth is meaningfully lower than platforms like Nykaa; management attributed to portfolio breadth but did not quantify gap.
October saw destocking due to GST 2.0 rollout; while November restocked, any future policy changes could disrupt volumes.
GST transition impact may extend beyond October, with trade restocking taking a couple of months to normalize.
Prolonged monsoon and potential weak winter could dampen demand for seasonal products like skincare and ice cream.
Analyst raised concern about digital-first competition and need to focus on mid and bottom of pyramid; management acknowledged need for sharper segmentation.
Body wash liquids penetration remains at only 2%, indicating slower adoption despite management's focus on premiumization.
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25, Q4 FY25
Inflation in palm oil, tea, and coffee not fully priced in, while deflation in crude oil is passed on quickly, creating a price-cost gap.
Mentioned in Q1 FY26, Q2 FY26, Q3 FY25
Ice cream demerger expected to complete in December quarter, with listing in Q4 FY26, subject to regulatory approvals.
Mentioned in Q1 FY25, Q1 FY26
Management acknowledged price decreases in home care due to both commodity deflation and competitive pressures, which could pressure margins and pricing power.
Mentioned in Q1 FY26, Q4 FY25
Management expects EBITDA margin to remain in the 22%-23% range for the next few quarters, with sequential gross margin improvement reinvested into the business.
Mentioned in Q1 FY25, Q2 FY25
Management aims to keep EBITDA margin at current ~23.8% levels, with some basis points fluctuation, through productivity savings and calibrated pricing.
Management expects FY27 top-line growth to exceed FY26, driven by improving macros and internal actions.
Depreciating rupee and divergent commodity trends (palm oil, tea, crude derivatives) could pressure margins if price increases lag.
View Risks →